Ascentage Pharma (AAPG) CEO Yang Dajun updates reported share and RSU holdings
Filing Impact
Filing Sentiment
Form Type
3/A
Rhea-AI Filing Summary
ASCENTAGE PHARMA GROUP INTERNATIONAL filed an amended Form 3 to update the initial ownership report for Chairman and CEO Yang Dajun. The filing lists existing holdings rather than new trades, covering ordinary shares, stock options and restricted stock units tied to the company’s ordinary shares.
Yang holds ordinary shares directly and also has indirect holdings through the Dajun Yang Dynasty Trust, his spouse, and HealthQuest Pharma Limited, an entity controlled by his spouse, as described in the footnotes. The report also shows options over 143,463 ordinary shares held directly and 103,364 held indirectly, with an exercise price of $8.14 and expiration on November 26, 2035.
The filing further discloses restricted stock units representing 143,463 ordinary shares directly and 103,364 indirectly. Each RSU converts into one ordinary share and vests in four equal installments on November 26 of 2026, 2027, 2028 and 2029, with no expiration date. Footnotes emphasize that many indirect positions are held by the trust or spouse and that Yang disclaims beneficial ownership beyond his economic interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Yang Dajun
Role
Chairman and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Options | -- | -- | -- |
| holding | Options | -- | -- | -- |
| holding | Restricted stock units | -- | -- | -- |
| holding | Restricted stock units | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Options — 143,463 shares (Direct);
Options — 103,364 shares (Indirect, See Footnote (6));
Restricted stock units — 143,463 shares (Direct);
Restricted stock units — 103,364 shares (Indirect, See footnote (6));
Ordinary Shares — 1,097,994 shares (Direct);
Ordinary Shares — 22,054,131 shares (Indirect, See Footnote (1))
Footnotes (1)
- Shares held by Dajun Yang Dynasty Trust, of which the Reporting Person is the investment advisor. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Shares held by Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Shares held by HealthQuest Pharma Limited, an entity controlled by the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. The stock options vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant. Securities held by the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029 and have no expiration date.
FAQ
What does the Ascentage Pharma (AAPG) Form 3/A filing show for Yang Dajun?
The Form 3/A shows Chairman and CEO Yang Dajun’s existing ownership in Ascentage Pharma, including ordinary shares, stock options, and restricted stock units. It is an amended initial statement of beneficial ownership rather than a record of new share purchases or sales.
How many Ascentage Pharma (AAPG) options does Yang Dajun hold according to this filing?
Yang Dajun holds options over 143,463 ordinary shares directly and 103,364 ordinary shares indirectly. These options have an exercise price of $8.14 and expire on November 26, 2035, with vesting described separately in the accompanying footnotes to the filing.
What restricted stock units (RSUs) in Ascentage Pharma (AAPG) are reported for Yang Dajun?
The filing reports restricted stock units representing 143,463 ordinary shares held directly and 103,364 held indirectly. Each RSU converts into one ordinary share and vests in four equal installments on November 26 of 2026, 2027, 2028 and 2029, with no expiration date.
How do indirect holdings work for Yang Dajun in Ascentage Pharma (AAPG)?
Indirect holdings are attributed to entities and relatives associated with Yang Dajun. Shares are held by the Dajun Yang Dynasty Trust, his spouse, and HealthQuest Pharma Limited controlled by his spouse. He disclaims beneficial ownership beyond his pecuniary interest, as highlighted in the detailed footnotes.
Does the Ascentage Pharma (AAPG) Form 3/A disclose any insider buying or selling by Yang Dajun?
The Form 3/A does not disclose insider buying or selling. It classifies the entries as holdings rather than transactions, with transaction counts for purchases, sales, exercises, gifts and tax withholdings all reported as zero in the transaction summary section.
How do Yang Dajun’s RSUs in Ascentage Pharma (AAPG) vest over time?
The restricted stock units vest in four equal installments on November 26, 2026, 2027, 2028 and 2029. Each RSU represents a contingent right to receive one ordinary share of Ascentage Pharma upon vesting and carries no stated expiration date in the disclosure.